AbbVie Inc. (ABBV) Income Statement
ABBV 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsABBV revenue and net income
Where ABBV's revenue goes
2025Each bar shows an amount and its share of revenue. ABBV kept 6.9% of revenue as net income.
ABBV profit margins
ABBV growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +8.6% | +1.8% | +6.0% | +10.3% |
| Gross profit | +8.9% | +1.9% | +7.1% | +8.9% |
| Operating income | +119.9% | +3.5% | +12.1% | +10.3% |
| Net income | −1.2% | −29.1% | −1.7% | −1.9% |
| EPS (diluted) | −1.2% | −10.2% | −1.0% | +8.9% |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ABBV quarterly EPS vs estimates
AbbVie beat the analyst EPS estimate in 7 of the last 8 quarters. Next report: October 30, 2026 (estimate $3.76).
ABBV income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $61.16B | $56.33B | $54.32B | $58.05B | $56.20B | $45.80B | $33.27B | $32.75B | $28.22B | $25.64B |
| Cost of revenue | $18.20B | $16.90B | $20.41B | $17.41B | $17.45B | $15.39B | $7.44B | $7.72B | $7.04B | $5.83B |
| Gross profit | $42.96B | $39.43B | $33.90B | $40.64B | $38.75B | $30.42B | $25.83B | $25.04B | $21.18B | $19.80B |
| Research & development | $9.10B | $12.79B | $7.67B | $6.51B | $8.05B | $7.75B | $6.79B | $10.75B | $5.33B | $4.58B |
| Sales, general & admin | $14.01B | $13.19B | $12.90B | $15.26B | $12.35B | $9.87B | $5.84B | $7.35B | $6.25B | $5.84B |
| Total operating expenses | $22.86B | $30.29B | $21.15B | $22.52B | $20.83B | $19.05B | $12.84B | $18.65B | $11.63B | $10.47B |
| Operating income | $20.09B | $9.14B | $12.76B | $18.12B | $17.92B | $11.36B | $12.98B | $6.38B | $9.54B | $9.34B |
| Interest income | $266.0M | $648.0M | $540.0M | $186.0M | $39.0M | $174.0M | $275.0M | $204.0M | $146.0M | $82.0M |
| Interest expense | $2.89B | $2.81B | $2.22B | $2.23B | $2.42B | $2.45B | $1.78B | $1.35B | $1.15B | $1.05B |
| Income before taxes | $6.60B | $3.72B | $6.25B | $13.48B | $12.99B | $3.40B | $8.43B | $5.20B | $7.73B | $7.88B |
| Income taxes | $2.36B | −$570.0M | $1.38B | $1.63B | $1.44B | −$1.22B | $544.0M | −$490.0M | $2.42B | $1.93B |
| Net income | $4.23B | $4.28B | $4.86B | $11.84B | $11.54B | $4.62B | $7.88B | $5.69B | $5.31B | $5.95B |
| EBITDA | $17.63B | $14.91B | $17.17B | $24.17B | $23.93B | $12.32B | $12.23B | $8.31B | $10.38B | $10.12B |
| EPS (diluted) | $10.00 | $10.12 | $11.11 | $13.79 | $12.70 | $10.51 | $8.94 | $7.91 | $5.59 | $4.82 |
| Gross margin | 70.2% | 70.0% | 62.4% | 70.0% | 69.0% | 66.4% | 77.6% | 76.4% | 75.0% | 77.2% |
| Operating margin | 32.8% | 16.2% | 23.5% | 31.2% | 31.9% | 24.8% | 39.0% | 19.5% | 33.8% | 36.4% |
| Net margin | 6.9% | 7.6% | 9.0% | 20.4% | 20.5% | 10.1% | 23.7% | 17.4% | 18.8% | 23.2% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $16.99B | $15.00B | $16.62B | $15.78B | $15.42B | $13.34B | $15.10B | $14.46B | $14.46B | $12.31B | $14.30B | $13.93B |
| Cost of revenue | $4.29B | $4.22B | $4.55B | $5.30B | $4.35B | $4.00B | $4.40B | $4.21B | $4.20B | $4.09B | $5.70B | $6.49B |
| Gross profit | $12.70B | $10.78B | $12.07B | $10.47B | $11.08B | $9.34B | $10.71B | $10.25B | $10.26B | $8.22B | $8.60B | $7.44B |
| Research & development | $2.34B | $2.47B | $2.58B | $2.32B | $2.13B | $2.07B | $6.77B | $2.13B | $1.95B | $1.94B | $2.21B | $1.72B |
| Sales, general & admin | $3.63B | $3.58B | $3.90B | $3.57B | $3.25B | $3.29B | $2.88B | $4.21B | $3.38B | $3.31B | $3.19B | $3.37B |
| Total operating expenses | $6.27B | $6.05B | $6.26B | $8.57B | $6.18B | $5.61B | $12.20B | $6.42B | $6.26B | $5.42B | $5.40B | $5.16B |
| Operating income | $6.43B | $4.73B | $5.81B | $1.90B | $4.89B | $3.73B | −$1.49B | $3.83B | $4.00B | $2.80B | $3.19B | $2.28B |
| Interest income | $67.0M | $72.0M | $59.0M | $72.0M | $62.0M | $73.0M | $92.0M | $129.0M | $220.0M | $207.0M | $186.0M | $157.0M |
| Interest expense | $746.0M | $717.0M | $714.0M | $739.0M | $740.0M | $700.0M | $702.0M | $720.0M | $726.0M | $660.0M | $564.0M | $555.0M |
| Income before taxes | $4.28B | $1.04B | $2.67B | $714.0M | $1.55B | $1.66B | −$2.27B | $2.08B | $2.15B | $1.75B | $1.21B | $1.95B |
| Income taxes | $662.0M | $342.0M | $853.0M | $526.0M | $613.0M | $372.0M | −$2.25B | $520.0M | $773.0M | $383.0M | $388.0M | $172.0M |
| Net income | $3.61B | $699.0M | $1.82B | $186.0M | $938.0M | $1.29B | −$22.0M | $1.56B | $1.37B | $1.37B | $822.0M | $1.78B |
| EBITDA | $8.61B | $3.69B | $5.37B | $3.52B | $4.34B | $4.40B | $535.0M | $4.88B | $5.00B | $4.49B | $3.85B | $4.74B |
| EPS (diluted) | $3.65 | $2.65 | $2.71 | $1.86 | $2.97 | $2.46 | $2.16 | $3.00 | $2.65 | $2.31 | $2.79 | $2.95 |
| Gross margin | 74.7% | 71.9% | 72.6% | 66.4% | 71.8% | 70.0% | 70.9% | 70.9% | 70.9% | 66.7% | 60.1% | 53.4% |
| Operating margin | 37.9% | 31.6% | 35.0% | 12.1% | 31.7% | 28.0% | −9.9% | 26.5% | 27.6% | 22.7% | 22.3% | 16.4% |
| Net margin | 21.3% | 4.7% | 10.9% | 1.2% | 6.1% | 9.6% | −0.1% | 10.8% | 9.5% | 11.1% | 5.7% | 12.8% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ABBV's financial statements (latest annual report filed February 20, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ABBV financial results
In fiscal year 2025 (ended December 31, 2025), AbbVie reported revenue of $61.2 billion, up 8.6% from the year before. It had net income of $4.2 billion (down 1.2%), a net profit margin of 6.9%. Diluted earnings per share came to $10.00. Over five years revenue grew at an average rate of 6.0% a year.
See the ABBV stock overview for the latest quote and news, or the ABBV chart for price history and technical indicators.
ABBV income statement FAQ
What is AbbVie's annual revenue?
AbbVie reported total revenue of $61.2 billion for fiscal year 2025, which ended on December 31, 2025. That was up 8.6% from $56.3 billion the previous year.
Is AbbVie profitable?
Yes. AbbVie reported net income of $4.2 billion in fiscal 2025, a net profit margin of 6.9%; its operating margin was 32.8%.
What is AbbVie's gross margin?
AbbVie's gross margin was 70.2% in fiscal 2025: for every $100 of revenue, AbbVie kept $70 after the direct cost of its products and services.
How much does AbbVie spend on research and development?
AbbVie spent $9.1 billion on research and development in fiscal 2025, 14.9% of revenue.
How fast is AbbVie growing?
Revenue grew 6.0% a year on average over the last five fiscal years, from $45.8 billion to $61.2 billion.
What are AbbVie's earnings per share?
AbbVie earned $10.00 per diluted share in fiscal 2025, compared with $10.12 a year earlier.
When will AbbVie report its next earnings?
AbbVie is expected to report results for the quarter ending September 30, 2026 on October 30, 2026 before the market opens.
When does AbbVie's fiscal year end?
AbbVie's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 20, 2026.